HELSINKI – Nanoform, a company that enhances how medicines work, has teamed up with cancer treatment developer PlusVitech to give a new purpose to aprepitant, a drug usually used to stop nausea. They’re using cutting-edge nano tech to make aprepitant into a hopeful lung cancer treatment.
Aprepitant is currently a large number of big capsules that patients take, which can be hard, especially for the ones who find swallowing difficult. Nanoform’s technique could change this, making the pills smaller and simpler to take, helping patients get the medicine they need without the hassle.
The partnership is moving forward quickly, following successful early human trials. They have started a more in-depth Phase 2 study with 24 people to see if a high dose of aprepitant can help those whose lung cancer hasn’t responded to other treatments.
Edward Hæggström, the CEO of Nanoform, expressed excitement about the collaboration. He said their nanotech is set to get new treatments to patients quicker than ever, and this lung cancer project is just one of many they’re working on to fight the disease.
Dr. Vicente Salinas and Fran Guillén of PlusVitech shared their eagerness to progress to a major Phase 3 trial with Nanoform’s help. They’re looking forward to delivering a new and improved form of the drug that’s easier for seriously ill patients to take.
Nanoform’s nano tech makes very tiny drug particles, allowing them to create smaller pills. Their special process is also eco-friendly, avoiding harsh chemicals and using recycled carbon dioxide instead.
Located next to Helsinki University, Nanoform’s facility is where this new form of aprepitant is being developed, alongside many other projects aiming to create better versions of existing drugs and completely new treatments.
